Cytosorbents (NASDAQ: CTSO) reported Q4 EPS of ($0.75), $0.57 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $29.36 million versus the consensus estimate of $8.88 million.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.